Bert Vander Cruyssen Selected Research

Antirheumatic Agents (DMARD)

3/2017	Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial.
12/2012	Comparison of the clinical expression of patients with ankylosing spondylitis from Europe and Latin America.
10/2007	Decrease of disease activity under ineffective therapy in DMARD-naive patients with early rheumatoid arthritis: role of antibody profiles and carriage of the HLA shared epitope in predicting decrease of disease activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bert Vander Cruyssen Research Topics

Disease

16	Rheumatoid Arthritis 01/2022 - 01/2005
3	Inflammation (Inflammations) 12/2019 - 02/2008
3	Ankylosing Spondylitis 07/2013 - 08/2007
2	Osteoarthritis 12/2018 - 06/2012
2	Arthritis (Polyarthritis) 12/2012 - 08/2007
2	Experimental Arthritis 02/2008 - 08/2007
1	Communicable Diseases (Infectious Diseases) 12/2019
1	Spondylarthropathies 01/2019
1	Pain (Aches) 12/2018
1	Rheumatic Diseases (Rheumatism) 01/2018
1	Joint Diseases (Joint Disease) 03/2017
1	Psoriatic Arthritis 06/2012
1	Disease Progression 06/2012
1	Thrombocytopenia (Thrombopenia) 07/2011
1	Necrosis 08/2007

Drug/Important Bio-Agent (IBA)

5	AntibodiesIBA 01/2022 - 01/2006
5	Rheumatoid FactorIBA 01/2022 - 01/2006
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2006
4	Peptides (Polypeptides)IBA 01/2022 - 01/2006
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2007
3	Antirheumatic Agents (DMARD)IBA 03/2017 - 10/2007
3	Methotrexate (Mexate)FDA LinkGeneric 03/2017 - 01/2010
3	Infliximab (Remicade)FDA Link 01/2010 - 01/2005
2	Leukocyte L1 Antigen Complex (Calgranulin)IBA 12/2019 - 01/2019
2	C-Reactive ProteinIBA 03/2017 - 06/2011
2	GlucocorticoidsIBA 03/2017 - 04/2015
2	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 12/2012 - 08/2007
2	HLA-B27 Antigen (HLA B27 Antigen)IBA 12/2012 - 06/2011
2	LigandsIBA 02/2008 - 08/2007
2	EpitopesIBA 10/2007 - 03/2007
1	Immunoglobulin A (IgA)IBA 01/2022
1	Edetic Acid (EDTA)FDA Link 12/2019
1	Etanercept (Enbrel)FDA Link 12/2018
1	cyclic citrullinated peptideIBA 01/2018
1	Biological ProductsIBA 01/2016
1	SteroidsIBA 12/2012
1	4-hexyloxyaniline (HOA)IBA 06/2012
1	Adalimumab (Humira)FDA Link 06/2012
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2012
1	Heparin (Liquaemin)FDA LinkGeneric 07/2011
1	Rituximab (Mabthera)FDA Link 01/2010
1	PhytochemicalsIBA 02/2008
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 02/2008
1	CytokinesIBA 08/2007
1	C-galactosylceramideIBA 08/2007
1	alpha-galactosylceramideIBA 08/2007
1	Pharmaceutical PreparationsIBA 08/2007
1	AntigensIBA 03/2007
1	Fibrinogen (Factor I)FDA Link 01/2006
1	acetyl 4-aminosalicylic acidIBA 01/2006

Therapy/Procedure

6	Therapeutics 06/2011 - 01/2005
3	Intravenous Infusions 01/2010 - 01/2005
1	Remission Induction 03/2017
1	Biological Therapy 01/2016
1	Hip Replacement Arthroplasty (Total Hip Replacement) 07/2013
1	Retreatment 01/2010